• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苯基偶氮吡啶和苯基偶氮吡唑氯钌(II)芳烃配合物:芳烃损失、水合作用及癌细胞细胞毒性

Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.

作者信息

Dougan Sarah J, Melchart Michael, Habtemariam Abraha, Parsons Simon, Sadler Peter J

机构信息

School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, U.K.

出版信息

Inorg Chem. 2006 Dec 25;45(26):10882-94. doi: 10.1021/ic061460h.

DOI:10.1021/ic061460h
PMID:17173447
Abstract

Ru(II) eta6-arene complexes containing p-cymene (p-cym), tetrahydronaphthalene (thn), benzene (bz), or biphenyl (bip), as the arene, phenylazopyridine derivatives (C5H4NN:NC6H5R; R = H (azpy), OH (azpy-OH), NMe2 (azpy-NMe2)) or a phenylazopyrazole derivative (NHC3H2NN:NC6H5NMe2 (azpyz-NMe2)) as N,N-chelating ligands and chloride as a ligand have been synthesized (1-16). The complexes are all intensely colored due to metal-to-ligand charge-transfer Ru 4d6-pi* and intraligand pi -->pi* transitions (eta = 5000-63 700 M-1 cm-1) occurring in the visible region. In the crystal structures of [(eta6-p-cym)Ru(azpy)Cl]PF6 (1), [(eta6-p-cym)Ru(azpy-NMe2)Cl]PF6 (5), and [(eta6-bip)Ru(azpy)Cl]PF6 (4), the relatively long Ru-N(azo) and Ru-(arene-centroid) distances suggest that phenylazopyridine and arene ligands can act as competitive pi-acceptors toward Ru(II) 4d6 electrons. The pKa* values of the pyridine nitrogens of the ligands are low (azpy 2.47, azpy-OH 3.06 and azpy-NMe2 4.60), suggesting that they are weak sigma-donors. This, together with their pi-acceptor behavior, serves to increase the positive charge on ruthenium, and together with the pi-acidic eta6-arene, partially accounts for the slow decomposition of the complexes via hydrolysis and/or arene loss (t(1/2) = 9-21 h for azopyridine complexes, 310 K). The pKa* of the coordinated water in [(eta6-p-cym)Ru(azpyz-NMe2)OH2]2+ (13A) is 4.60, consistent with the increased acidity of the ruthenium center upon coordination to the azo ligand. None of the azpy complexes were cytotoxic toward A2780 human ovarian or A549 human lung cancer cells, but several of the azpy-NMe2, azpy-OH, and azpyz-NMe2 complexes were active (IC50 values 18-88 microM).

摘要

已合成了含有对异丙基苯(p-cym)、四氢萘(thn)、苯(bz)或联苯(bip)作为芳烃配体、苯基偶氮吡啶衍生物(C5H4NN:NC6H5R;R = H(azpy)、OH(azpy-OH)、NMe2(azpy-NMe2))或苯基偶氮吡唑衍生物(NHC3H2NN:NC6H5NMe2(azpyz-NMe2))作为N,N-螯合配体以及氯离子作为配体的钌(II)η6-芳烃配合物(1 - 16)。由于在可见光区域发生金属到配体的电荷转移Ru 4d6-π和配体内π→π跃迁(ε = 5000 - 63700 M-1 cm-1),这些配合物都具有强烈的颜色。在[(η6-p-cym)Ru(azpy)Cl]PF6(1)、[(η6-p-cym)Ru(azpy-NMe2)Cl]PF6(5)和[(η6-bip)Ru(azpy)Cl]PF6(4)的晶体结构中,相对较长的Ru-N(azo)和Ru-(芳烃质心)距离表明苯基偶氮吡啶和芳烃配体可作为对Ru(II) 4d6电子的竞争性π-受体。配体吡啶氮的pKa值较低(azpy为2.47,azpy-OH为3.06,azpy-NMe2为4.60),表明它们是弱σ-供体。这与它们的π-受体行为一起,增加了钌上的正电荷,并与π-酸性的η6-芳烃一起,部分解释了配合物通过水解和/或芳烃损失的缓慢分解(对于偶氮吡啶配合物,t(1/2) = 9 - 21 h,310 K)。[(η6-p-cym)Ru(azpyz-NMe2)OH2]2+(13A)中配位水的pKa为4.60,这与钌中心与偶氮配体配位后酸度增加一致。没有一种azpy配合物对A2780人卵巢癌细胞或A549人肺癌细胞具有细胞毒性,但几种azpy-NMe2、azpy-OH和azpyz-NMe2配合物具有活性(IC50值为18 - 88 μM)。

相似文献

1
Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.苯基偶氮吡啶和苯基偶氮吡唑氯钌(II)芳烃配合物:芳烃损失、水合作用及癌细胞细胞毒性
Inorg Chem. 2006 Dec 25;45(26):10882-94. doi: 10.1021/ic061460h.
2
Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.氯半夹心钌(II)配合物:螯合的N,N-配体对水解、鸟嘌呤结合及细胞毒性的影响。
Inorg Chem. 2007 May 14;46(10):4049-59. doi: 10.1021/ic062350d. Epub 2007 Apr 19.
3
The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.联吡啶和联吡啶二醇钌(II)芳烃配合物的化学性质对比及其对癌细胞的细胞毒性
Inorg Chem. 2008 Dec 15;47(24):11470-86. doi: 10.1021/ic801361m.
4
Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.通过 N,O-螯合配体调节锇芳烃配合物的水解水相化学以实现癌细胞毒性。
J Am Chem Soc. 2007 Mar 21;129(11):3348-57. doi: 10.1021/ja068335p. Epub 2007 Feb 24.
5
Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.钌(II)芳环抗癌配合物与氧化还原活性二胺配体。
Inorg Chem. 2009 Oct 5;48(19):9444-53. doi: 10.1021/ic9013366.
6
New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.新型细胞毒性水溶性双(2-苯基偶氮吡啶)钌(II)配合物
J Med Chem. 2003 Apr 24;46(9):1743-50. doi: 10.1021/jm021110e.
7
Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.在生理条件下调节锇(II)和钌(II)芳烃配合物的反应活性。
J Am Chem Soc. 2006 Feb 8;128(5):1739-48. doi: 10.1021/ja055886r.
8
Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.9-乙基鸟嘌呤与混合配体化合物α-[Ru(2-苯基偶氮吡啶)(2,2'-联吡啶)Cl2]的配位作用。一种前所未有的配体位置移动,与这类[RuL2Cl2](L = 2-苯基偶氮吡啶或2,2'-联吡啶)配合物的细胞毒性相关。
Inorg Chem. 2004 Aug 9;43(16):4935-43. doi: 10.1021/ic035390f.
9
Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.含N,N-、N,O-和O,O-螯合配体的细胞毒性钌(II)芳烃配合物的构效关系
J Med Chem. 2006 Nov 16;49(23):6858-68. doi: 10.1021/jm060596m.
10
Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.新型钌(II)η6 - 芳烃咪唑配合物的合成、表征及体外评价
J Med Chem. 2006 Sep 7;49(18):5552-61. doi: 10.1021/jm060495o.

引用本文的文献

1
Molecular Design Considerations for Azobenzene Anolytes.偶氮苯阳极电解液的分子设计考量
ACS Omega. 2025 Jun 12;10(24):26199-26206. doi: 10.1021/acsomega.5c05073. eCollection 2025 Jun 24.
2
Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity.自组装钌和锇纳米系统通过干扰代谢活性展现出强大的抗癌特性。
Inorg Chem Front. 2022 Jun 7;9(11):2594-2607. doi: 10.1039/d2qi00423b. Epub 2022 Apr 12.
3
Synthesis and Cytotoxic Activity Study of Novel 2-(Aryldiazenyl)-3-methyl-1-benzo[]indole Derivatives.
新型 2-(芳基亚氨基)-3-甲基-1-苯并吲哚衍生物的合成及细胞毒性活性研究。
Molecules. 2021 Jul 12;26(14):4240. doi: 10.3390/molecules26144240.
4
Size-selective Pt siderophores based on redox active azo-aromatic ligands.基于氧化还原活性偶氮芳族配体的尺寸选择性铂铁载体。
Chem Sci. 2020 Aug 20;11(34):9226-9236. doi: 10.1039/d0sc02683b.
5
The Anticancer Activities of Some Nitrogen Donor Ligands Containing bis-Pyrazole, Bipyridine, and Phenanthroline Moiety Using Docking Methods.使用对接方法研究含双吡唑、联吡啶和菲咯啉部分的一些含氮供体配体的抗癌活性。
Bioinorg Chem Appl. 2018 Jun 4;2018:5796287. doi: 10.1155/2018/5796287. eCollection 2018.
6
The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.抗癌钌(II)配合物的发展:从单分子化合物到纳米材料。
Chem Soc Rev. 2017 Oct 2;46(19):5771-5804. doi: 10.1039/c7cs00195a.
7
Crystal structure of [3-amino-2-(phenyl-diazenyl)-pyridine]chlorido-(η(6)-p-cymene)-ruthenium(II) chloride.[3-氨基-2-(苯基重氮基)-吡啶]氯代-(η(6)-对异丙基苯)-钌(II) 氯化物的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Sep 26;71(Pt 10):m185-6. doi: 10.1107/S2056989015017466. eCollection 2015 Oct 1.
8
Metal-based drugs.金属类药物。
Sci Prog. 2014;97(Pt 1):1-19. doi: 10.3184/003685014X13898980185076.
9
Differences in the CO photolability of - and - [RuCl(azpy)(CO)] complexes: Effect of metal-to-ligand back-bonding.- 和 - [RuCl(偶氮吡啶)(CO)] 配合物的CO光解性差异:金属-配体反馈键合的影响。
Inorganica Chim Acta. 2013 Oct 1;407. doi: 10.1016/j.ica.2013.07.047.
10
Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells.分析钌-酮康唑和钌-克霉唑配合物对癌细胞的细胞毒性作用。
Cell Biol Toxicol. 2013 Dec;29(6):431-43. doi: 10.1007/s10565-013-9264-z. Epub 2013 Nov 24.